Table 1.

Multivariate analysis of clinicopathological parameters and HSPC111 expression in two breast cancer cohorts

Variable	Hazard ratio (95% confidence interval)	P
Uppsala cohort
Tumor size > 20 mm	3.20 (1.65 to 6.21)	0.0006
Lymph node positive	3.13 (1.79 to 5.46)	< 0.0001
HER2 high expression	1.82 (1.02 to 3.27)	0.0444
HSPC111 high expression	2.29 (1.30 to 4.03)	0.0043
HSPC111 high expression	2.51 (1.43 to 4.41)	0.0014
MYC high expression	1.89 (1.06 to 3.36)	0.0305
NKI cohort
Tumour size > 20 mm	1.90 (1.10 to 3.28)	0.0223
Tumour grade > 2	2.04 (1.22 to 3.44)	0.0070
ER positive	0.67 (0.38 to 1.18)	0.1636
PR positive	0.56 (0.32 to 1.00)	0.0490
HER2 high expression	1.46 (0.87 to 2.43)	0.1493
HSPC111 high expression	1.29 (0.79 to 2.12)	0.3074
HSPC111 high expression	1.89 (1.17 to 3.08)	0.0097
MYC high expression	1.83 (1.14 to 2.93)	0.0118

NKI, Nederlands Kanker Instituut.